Daniel C Strobl
Overview
Explore the profile of Daniel C Strobl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luecken M, Gigante S, Burkhardt D, Cannoodt R, Strobl D, Markov N, et al.
Res Sq
. 2024 Apr;
PMID: 38645152
With the growing number of single-cell analysis tools, benchmarks are increasingly important to guide analysis and method development. However, a lack of standardisation and extensibility in current benchmarks limits their...
2.
Sikkema L, Ramirez-Suastegui C, Strobl D, Gillett T, Zappia L, Madissoon E, et al.
Nat Med
. 2023 Jun;
29(6):1563-1577.
PMID: 37291214
Single-cell technologies have transformed our understanding of human tissues. Yet, studies typically capture only a limited number of donors and disagree on cell type definitions. Integrating many single-cell datasets can...
3.
Heumos L, Schaar A, Lance C, Litinetskaya A, Drost F, Zappia L, et al.
Nat Rev Genet
. 2023 Mar;
24(8):550-572.
PMID: 37002403
Recent advances in single-cell technologies have enabled high-throughput molecular profiling of cells across modalities and locations. Single-cell transcriptomics data can now be complemented by chromatin accessibility, surface protein expression, adaptive...
4.
Vornholz L, Isay S, Kurgyis Z, Strobl D, Loll P, Mosa M, et al.
Sci Adv
. 2023 Mar;
9(11):eadd8564.
PMID: 36921054
Immune checkpoint inhibitors (ICIs) enhance anticancer immunity by releasing repressive signals into tumor microenvironments (TMEs). To be effective, ICIs require preexisting immunologically "hot" niches for tumor antigen presentation and lymphocyte...
5.
Kuhn L, Valentin S, Stojanovic K, Strobl D, Babushku T, Wang Y, et al.
Front Immunol
. 2022 Sep;
13:913275.
PMID: 36110848
Activation of CD40-signaling contributes to the initiation, progression and drug resistance of B cell lymphomas. We contributed to this knowledge by showing that constitutive CD40-signaling in B cells induces B...